Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

May 31, 2022 by Business Wire Health: Oncology News

Key Facts

  • LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022.
  • “Potential Therapeutic Utility of Direct AMP Kinase Activation for X-Linked Adrenoleukodystrophy (ALD)” > > Tweet this * Jefferies 2022 Global Healthcare Conference (in person) - New York, New York, USA Date: June 8-10, 2022 Thomas Kuhn, CEO and other members of the Poxel management team will be available for one-on-one in-person meetings on June 9-10, 2022.

    • JMP Securities 2022 Life Science Conference (in person) - New York, New York, USA Date: June 15-16, 2022 Thomas Kuhn, CEO and other members of the Poxel management team will be available for one-on-one in-person meetings on June 16, 2022.
    • 8th Congress of the European Academy of Neurology (in person) – Vienna, Austria Date: June 25-28, 2022 Poxel will present an e-poster on its drug candidate PXL770 entitled: "Potential Therapeutic Utility of Direct AMP Kinase Activation for X-Linked Adrenoleukodystrophy (ALD)".

Click To Read Full Article

GEOGRAPHY
PERSON
GROUP
PRODUCT
ORGANIZATION
WORK OF ART
EVENT
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?